Altamira Therapeutics Receives Philippines FDA Approval for Bentrio Nasal Spray
HAMILTON, BERMUDA/ACCESSWIRE/May 23, 2022/ Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutic products that address significant unmet medical needs, today announced that Bentrio™ has been approved by the Philippines Food and Drug Administration (FDA) and that it is now authorized for marketing in this country. country of 115 million people.
The product will be marketed through the local subsidiary of Wellesta Holdings Pte Ltd, Singapore (“Wellesta”). Under a previously announced marketing and distribution agreement with Altamira, expanded in February to include the Philippines, Wellesta will market and distribute Bentrio in India, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Vietnam and Morocco (the “Territory”). In this territory, Bentrio had already received authorization in Singapore and Malaysia.
“We are thrilled to see the Philippines join the growing list of countries where Bentrio is approved,” commented Thomas Meyer, Founder, President and CEO of Altamira Therapeutics. “Asia, with its large population and rapidly growing middle class, represents a significant sales opportunity for Bentrio. We look forward to expanding its availability, over the counter, to provide more consumers with protection against airborne allergens and viruses.
Last week, the company announced positive early data from its house dust mite challenge (HDM) clinical trial, conducted in Canada, which demonstrated a statistically significant reduction in nasal symptoms compared to untreated controls, as well as good tolerance and good security. HDM allergens are the primary cause of respiratory allergies (i.e. allergic rhinitis and allergic asthma). Unlike plant-based allergens, which tend to be seasonal (eg pollen/hay fever), HDMs can be present all year round.
Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. When applied in the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with the cells; in addition, the composition serves to bind these particles and to promote their evacuation and to moisten the nasal mucosa. Together, this is designed to reduce the risk of viral upper respiratory infections and promote relief of allergy symptoms. For more information visit:
Bentrio is distributed in some European countries and is expected to be available through distributors in other countries in Europe, Asia and the MENA region. In the United States, Altamira has filed a 510(k) filing for Bentrio in the treatment of allergic rhinitis, which is currently under review by the FDA.
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is dedicated to developing therapeutic products that address significant unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2) and the development of therapies for the intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it has its headquarters in Hamilton, Bermuda, and its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/.
This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than statements of fact statements and may include statements that address future operational, financial or business performance or Altamira Therapeutics’ strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “could”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimates”, “predicts”, “plans”, “potential”, “outlook” or “continues”, or the negative form of these terms or any other comparable terminology. Forward-looking statements are based on the current expectations and beliefs of management and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such statements.These risks and uncertainties include, but are not limited to, approval and timing of commercialization of AM-301, Altamira Therapeutics’ need and ability to secure substantial additional funding to further develop its product candidates, timing and conduct of studies clinical trials of Altamira Therapeutics’ product candidates, the clinical utility of Altamira Therapeutics’ product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics’ intellectual property position and the financial condition of Altamira Therapeutics’ ‘Altamira Therapeutics, including the impact of any future acquisitions, dispositions, partnerships, licensing transactions or changes to Altamira Therapeutics’ capital structure, including future issuances of securities. These risks and uncertainties also include, but are not limited to, those described under “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the fiscal year ended December 31, 2021, and in other documents filed by Altamira Therapeutics with the SEC, which are available free of charge on the Securities Exchange Commission’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to such risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics undertakes no obligation to update them in light of new information, future developments or otherwise, except as required by applicable law. required.
THE SOURCE: Altamira Therapeutic
See the source version on accesswire.com: